Any current/future capex/capital investment/strategic investment?

Planned capital expenditure for FY '27 is around INR 80-85 crores, primarily funded through internal accruals; no significant additional debt expected. Focus on brownfield expansions mainly at Mysore and Satara (Mahad plant supply). Addition of 4 new thin wall machines at Panipat in July, doubling thin wall capacity, aiming to increase capacity utilization from 20-25% to 40-50% next year. New land acquired near Sultanpur for a Pharma plant; construction expected to start soon after land possession, with commercial production targeted by the end of FY '27 (possibly January 2028). Consol

Any current/future new fundraising through debt or equity?

No additional debt is expected for capacity expansion in FY '27; internal accruals will fund capex. Planned capital expenditure for FY '27 is around INR 80-85 crores, mostly funded from internal cash generation. Cash generation this year is around INR 100 crores net after dividend, sufficient for planned capex and debt repayment. Debt repayment will happen from cash accruals, and overall debt is not expected to increase. No mention of new equity fundraising or share issuance in the provided transcript. The company focuses on brownfield expansions with limited capital needs going forward.

Future growth expectations in sales/revenue/volumes?

Volume growth for FY '27 is expected to be between 10% to 13%, primarily because Pharma volumes will remain low despite high value growth. Value growth guidance for FY '27 is 13% to 15%, driven by higher realizations and client additions, especially in Food, FMCG, Paints, and ABG segments. The Lubricant segment is expected to remain stagnant with no major volume growth. Asian Paints and ABG are key growth drivers, with Asian Paints expected to improve from ~3.5% annual growth to around 10% in FY '27. Food and FMCG, especially from the North (Panipat) plant, are anticipated to grow at a

Future growth expectations in earnings/operating earnings/profits/EPS?

Targeting at least INR 210 crores EBITDA in FY 2026-27, up from INR 173 crores, indicating ~20% growth. Aiming for 13%-15% value growth and 10%-13% volume growth in FY 2026-27. EBITDA per kg expected to improve to 42.5 in FY 2026-27 from 40.7 in FY 2025-26, with potential to reach 43-44 in FY 2027-28. ROCE expected to rise from 12.4% to around 13.5%-14% in FY 2026-27, possibly reaching 15% by FY 2027-28. Profitability gains driven by increased business, operational efficiencies, consolidation of plants, and capacity utilization growth (70%+ expected in FY 2026-27). No major downside expected b

IN US

Sale is live|00:00:00left today

Mold-Tek Packaging LtdQ1 FY26Industrial Products

Mold-Tek Packaging Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹702P/E: 32.3Market Cap: ₹2.3K CrSector: Industrial Products

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Volume growth for FY '27 is expected to be between 10% to 13%, primarily because Pharma volumes will remain low despite high value growth.
→Value growth guidance for FY '27 is 13% to 15%, driven by higher realizations and client additions, especially in Food, FMCG, Paints, and ABG segments.
→The Lubricant segment is expected to remain stagnant with no major volume growth.
→Asian Paints and ABG are key growth drivers, with Asian Paints expected to improve from ~3.5% annual growth to around 10% in FY '27.
→Food and FMCG, especially from the North (Panipat) plant, are anticipated to grow at around 20%.
→EBITDA per kg is targeted to improve to 42.5 in FY '27 and 43-44 in FY '28 due to operational efficiencies.
→Revenue is expected to cross INR 1,000 crores in FY '27, with a target to surpass INR 1,200 crores by FY '28.

Margin guidance

Category 2

→Targeting at least INR 210 crores EBITDA in FY 2026-27, up from INR 173 crores, indicating ~20% growth.
→Aiming for 13%-15% value growth and 10%-13% volume growth in FY 2026-27.
→EBITDA per kg expected to improve to 42.5 in FY 2026-27 from 40.7 in FY 2025-26, with potential to reach 43-44 in FY 2027-28.
→ROCE expected to rise from 12.4% to around 13.5%-14% in FY 2026-27, possibly reaching 15% by FY 2027-28.
→Profitability gains driven by increased business, operational efficiencies, consolidation of plants, and capacity utilization growth (70%+ expected in FY 2026-27).
→No major downside expected barring unforeseen events like war impact; prospects could be better than guided.
→Revenue expected to cross INR 1,000 crores in FY 2026-27 and potentially INR 1,200 crores by FY 2027-28.

3 more insights locked — sign up free to unlock

Fundraise plans

→No additional debt is expected for capacity expansion in FY '27; internal accruals will fund capex.
→Planned capital expenditure for FY '27 is around INR 80-85 crores, mostly funded from internal cash generation.
→Cash generation this year is around INR 100 crores net after dividend, sufficient for planned capex and debt repayment.
→Debt repayment will happen from cash accruals, and overall debt is not expected to increase.
→No mention of new equity fundraising or share issuance in the provided transcript.
→The company focuses on brownfield expansions with limited capital needs going forward.

Order book

The transcript provided does not explicitly mention the current or expected order book or pending orders for Mold-Tek Packaging Limited. However, some relevant points related to order inflows and customer additions can be inferred: - New clients have been onboarded at the Panipat facility, especially in FMCG/thin wall packaging, contributing to increasing volumes. - Recent signing of a couple of big clients in the North region who were previously buying from competitors. - Existing large clients like Asian Paints, ABG, and HUL are maintaining or increasing their demand. - Growth in Paints segment volumes driven largely by ABG and Asian Paints. - Pharma segment demand is growing on replacement demand and export recovery. - Pharmaceutical packaging products are under development, with commercial revenues expected to start adding in 2-3 quarters. No specific orderbook numbers or pending orders data are disclosed.

Capex plans

Yes

→Planned capital expenditure for FY '27 is around INR 80-85 crores, primarily funded through internal accruals; no significant additional debt expected.
→Focus on brownfield expansions mainly at Mysore and Satara (Mahad plant supply).
→Addition of 4 new thin wall machines at Panipat in July, doubling thin wall capacity, aiming to increase capacity utilization from 20-25% to 40-50% next year.
→New land acquired near Sultanpur for a Pharma plant; construction expected to start soon after land possession, with commercial production targeted by the end of FY '27 (possibly January 2028).
→Consolidation of Hyderabad plants from 5 to 2 units to improve efficiency and reduce overheads.
→Continued investments to support growth in Pharma packaging and sustainable capacity utilization crossing 70% from next year onwards.

How does Mold-Tek Packaging Ltd rank vs peers in Industrial Products?

Pro feature

1Mold-Tek Packaging Ltd

Rev 3Mar 2

See full Industrial Products sector rankings

Want more stocks like Mold-Tek Packaging Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio